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The di spos ition of o r:1l iso trctinoin to the skin and the 
effe cts of the drug on the vitamin A levels in se rum and 
skin were studied in 17 patien ts w ith nod ul ocystic acne. 
All patients received 0.5 mg/kg/da y for 3 month s and 8 
patients continued treatment w ith 0.75 m g/kg/day for an-
o ther 3 month s. Th e parent dru g, the m aj or metabo lite (4-
oxo-iso tretino in), and 2 natural retin o ids (retin ol and de-
hydroretinol) were mo nito red in serum and bio psies o f 
unin volved skin , usin g adsorption hi gh-press ure liquid 
chro matograp hy. D urin g the initia13 months of trea tment 
the mean isotretinoin level in the se rum was 145 ng/ ml and 
in th e epider.mis 73 ng/g. Th e co rrespondin g values for 4-
oxo-i so tretinoin were 615 and 113 ng/g, respectively . Even 
-----------
I sotretin o in is a hi ghl y effective remedy fo r seve re acne, and marked ly suppresses sebum secretion even in low doses II ,21. An o ther sy n thetic retin o id, c tret ina te, kn own to impro ve a variet y of knatini zin g skin disorders, is not nea rl y as efTec-tivc as iso tre tino in in acne \3 \. The reason for thi s differen ce 
in effect is no t understood; no r is the p recise me chani sm of action 
or th e drug. When attemptin g to elucidate these matters it is 
impo rtant to keep in mind that isotretin o in pro bably lies in th e 
pathway of vita min A 1 (retin o l) metabo li sm \4-TJ. 
Vitamin A is esse nt ial fo r pro per differentiation of epithelia, 
in clu ding th ose lining th e hair fo lli cles and th e sebaceo us g lands 
IS\. Altho ugh the fo lli cul ar keratini zat io n is disturbed both in 
vitam in A defic iency and in acne vul ga ris !9 \, the impo rtance o f 
hypov ita min osis A in the pathogenes is o f acne is still hi ghl y co n-
troversial. Recentl y the seru m concentratio ns o f retin o l and ret-
in ol-b in d ing prote in (L< BP) and th e skin concentrati o ns of retinol 
were fou nd to be so mew hat lower in acne patien ts th an in hea lthy 
controls [1 0-12 \. 
In the present stud y we address the q uestio n o f w hether iso-
tretino in th erapy interferes w ith the plasm a tran spo rt o f vitamin 
A (in volvin g R BP and prea lbumin) o r w ith th e occurren ce oC2 
predo min ant fo rm s of vitamin A in th e skin , namely ret inol and 
de hydro retin o l (v itam in A2) \1 3 \. Additi o nall y, the se rum and 
skin k vcl s o f isotretino in and its main metaboli te were stu d ied 
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at the highest dosage there was no progressive accumula-
tion of isotretinoin in serum, epidermis, o r subcuti s. After 
discontinuation of therapy the drug di sappea red fro m bo th 
serum and skin within 2-4 weeks . The serum transport of 
vitamin A , monitored by the concentration s of retino l , 
retinol-binding protein , and prealbumin (transthyretin), was 
not affected by the trea tment . By contrast, the retinol level 
in the epidermis increased b y an average of 53% (p < 0.01) 
and the dehydro retino llevel decreased by 79% (p < 0.001 ) 
as a result of 3 months of trea tment . Both changes were 
revers ible. T he results su ggest that isotretin oin therapy in-
terferes with the endogenous vitamin A m etabolism in the 
skin . J l n11est Dermatol 86:384-389, 1986 
by a novel hi gh-press ure li quid chro matography (HPLC) pro-
ced ure. 
MATERIALS AND M ETH ODS 
Patients The study comprised 17 patients (13 m en, 4 women) 
aged 19-40 (mea n 25.3) years w ith nodulocys ti c acne, parti ci-
patin g in an open clinical trial of oral isotretinoin . The m ean 
durati o n of the disease was 9.6 (0.5-26) years. Topical acne prep-
arations were withdrawn at least 3 weeks prior to isotretinoin 
therapy . N o concomitant systemi c med icatio n was allo wed. Three 
fema les started w ith o ral contra cepti ves 2 months before the trial 
and co ntinu ed to take them throughout the stud y. 
Two health y male subj ects served as placebo-treated contro ls. 
All patients were in good general health and, except for a staph-
ylococca l carbuncl e in 1. patient:, no co ncurrent diseases devel-
o ped . T here was no dropout from the study . O ur patients took 
part in a mu lti center trial, the excellent clinical res ults of w hi ch 
wi ll be presented elsew here. 
Written info rm ed consent was obtai ned from the patients, and 
the stud y was approved by the Ethi ca l Committee of Uppsala 
Uni ve rsity. 
Treattnent Ca psules co ntainin g 5, "I 0, or 20 m g of iso tretinoin 
(Roaccutane) in o il were supplied by H o ffm ann-La Roche & Co. , 
AG , I3:~ s el , Switze rland. The initial ora l dose was 0.5 m g/kg/d ay 
and the dru g was taken with meals twi ce daily for 3 m onths. At 
th e end of thi s period the dose w as adju sted acco rdin g to the 
clini ca l response. Thus, 8 patients with less than 66% imp rove-
ment received 0 . 75 m g/ kg/day fo r another 3 mo nths, w hereas 
the other 9 patients stopped trea tment. 
Placebo ca psules, not containin g iso tretino in, were provided 
by 1-lo ffman-La Roche and administered (5 per day) to the 2 
hea lth y contro ls. 
Tissue and Blood Collection Epidermal shave biopsies (10-25 
mg) and subcutaneo us fat samples (5-15 m g) w ere obta ined from 
U022-2U2X/tl6/$03.50 C opyright © 19tl6 by The Society for Inves tiga tive Dermatology, In c. 
384 
VOL. 86, N O. 4 APRI L 1 \1~6 
p a re ntl y no rmal skin o n the buttock as described el sew here 
[f3. 14) . T he bio psies w ere taken sho rtl y befo re iso tretin o in tiler-
and a fter I , 3, and 6 m o nths o f therapy and a ga m approx J-
:-::.Ite l y ·1, 3, and 6 mo nths after ~ isco ntinuatio n o f the dru g. The 
tissu es wcrc snap-frozen o n dry ICC and sto red fo r 1-3 m o nths at 
- 70oC until analyzed . Fas tm g b lood samples were dra w n l:l- 18 
h afte r a prev io us close, using vacuum g !Jss tubes w rapped in 
a luminum fo il. Serum was separated by centnfuga n o n and s to red 
at -70oC until processed. 
Chemicals M ethano l, n-hexa ne, and eth yl acetate o f HPLC 
ra d e wcrc fro m Ra tl~ burn C he mi cal s Ltd ., Walkerburn , U.K . ~l aci a l aceti c acid o t analytica l qu ality w as fro m _ E. Merck, 
Darms tad t, W est German y. E thanol o f spectrog raphic g rade was 
f r o m Svcnsk Sprit AB, Sweden. DeJo nJzcd w ater was passed 
th ro u g h a Milli-Q w ater punficat1o n system (Md!Jpo re Co rp . , 
B d fo rd M assachusetts) be fo re usc. eCrys t~ ll i n e all-1n111s r_etino l an d trctino in (all - tra11s-retino ic acid) 
were purchased fro m S1g m a C hen11cal Co. ,_ SL Lo tns , M1 sso un . 
fso tre tin o in , 4-oxo-Jsotretm o m, 4-oxo-tretm o Jn, th e ca rboxy li c 
aci d o f etrctin atc (Ro 1 0- 1670), 13_-ris isomer of l~o 10-1670 (Ro 
13- 7652) , an aro m ati c analog ue o f all-t ra ilS _ rc tm ol (Ro _1 2-0586), 
11 13-di-cis-tretino in , and 3,4-dehyclro retmol we re g1fts fro m 
H~ffm ann-La Roche & Co., AG, Basel, Switzerhmcl o r Nutley , 
New J e rsey. 
I nternal Standard T he intern al stand ard so lutio n was prepared 
in a volum etr ic fl ask by di ssolving 2. 9 J-Lg o f aro mati c ana logue 
of re tin o l, 5.5 J-Lg of carbox yli c aCJd o f etretmate, and 3. 0 mg o f 
b ut ylated hydroxyto luene in I 20 ml of eth ano l. The so lutio n was 
sto red at - 70°C unclcr nitrogen . 
Saponification and Extraction A previo usly described pro-
cedure [1 5) was used w 1th so m e m od1fi cat1o ns. Thc tiss ue spec-
imen o r serum (100-500 J-L I) was add ed to a screw-ca pped g lass 
tu be containing 100 J-LI of SO% KO H and 250 J-LI o f the stan da rd 
so lutio n . T he tubes were flu shed w ith nit rogen, scaled , and heated 
at 80°C fo r 15 min o n a Mul ti-block hea ter (La b-line In strum ents 
Inc., Melrose Park , Illi no is). After the tubes had been cooled in 
ice wa te r, 0. 5 ml of H20 and 4 ml o f hexane w ere ad ded . The 
rubes were flu shed w ith nitrogen and vigo ro usly shaken fo r 5 
m in. T he hexa ne la yer w as rem oved after centrifuga ti o n fo r 2 
m in at 600 g. T he extrac tio n was repea ted o nce w ith a fres h 
portio n o f hexa ne. The co mbined supernata~1t (co ntammg neut ra l_ 
re tin o ids) w as eva po rated to dryness at 50 C un de r a s trca m o f 
Figure 1. H PLC of (a) neut ra l and (b) acidic rct-
ino ids added to a vita nun A-depleted sktn sa mple 
subsequentl y hydrolyzed and extracted with hex-
ane (calibration runs). Fo r details sec Nlatrrials a111i 
Methods. T he follow in g retinoid standards were 
added: all-trailS retinol (p eak '/), dchyd rorctinol 
(peak 2), aromatic analogue of all-trails retinol 
(internal standard ; peak 3), isotn:tinoin (peak 4), 
carboxylic acid of ctrctinate (internal standard ; 
peak 8) and 4-oxo-isotrctin oin (p eak 12). Addi-
tional peaks appea ring durin g :uJJ iys is were: tre-
tinoin (p eak 5); I I , 13-di-cis-tretin oin (pea k 6), 13-
cis ca rboxylic acid of etrctinatc (peak 7), and --1 -
oxo-tretinoin (peak II ). Peaks 9 a11d 10 were not 
iden tified. The base-line shifts in (b) at I U and I H 
min after sa mpl e injection (i11j) were the results 
of a discontinuous change in so lvent mi xture gra-
dients. Owin g to the high extent of arti factllal 
isomeriza tion of 4-oxo-isotrctinoin, the su1n of 
the heights of peaks 11 a111i 12 was related to the 
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nitrogen. A second ex trac t (containing acidi c retin o ids) was o b-
tained after adj ustm ent o f th e rem aining aqueous phase to pH 
4-5 fo ll owed by extract io n w ith 4 ml of hexa ne as above. Both 
the eva po rated ex tracts (one containin g neutra l retin o ids and the 
o ther containing acidi c retino ids) were disso lved in 75 J-LI of th e 
mobile phase (see below) by ultrasoni c agitat io n fo r 3 m in . Befo re 
injecti o n o n to the HPLC co lumn , th e sa mple was centrifuged fo r 
5 min at 1300 g to rem ove parti cula te matters. 
All sa mples were handled und er ye llow .li ght to minimize pho-
todestru cti o n o f the ret ino ids. 
Chr01natography T he HPLC equipment incl uded an Altcx 
Model 11 0 so lvent m etering pump w ith a Model 11 0-40 press ure 
filter (A itex Scienti fic Inc., Berkeley , Ca li fo rnia), a Rh eod ync 
Model 7 120 sample inj ecto r valve equipped w ith an ex tern al 50 
J-LI sa mp le loop (Hheocl yne In c., Berkeley, Ca li fo rnia), and a Model 
440 abso rbance detecto r (Wa ters Assoc. In c., Mil fo rd . Massa-
chusetts) operating at fixed waveleng ths (340 and 365 nm ). Two 
d ual-pen chart reco rders (Lin ea r Instrum ents, Irvine, C:1 li fo rnia) 
were fitted w ith inputs of 1 and I 0 m V, respectively, allow ing a 
wide range of optim al detecti o n (0 .02-0.002 ti.dl -sca lc :~bso r­
bancc) . . Adsorptio n chro m atograph y was performed at am bient 
tem perature o n a 150 X 4.6 mm (i.e! .) column packed w ith 5-
J-Lm Nucleos il sili ca gel (Skand inaviska GeneTec A I3, Ku ngs-
backa , Sweden). A G uarci-PAK prccolumn mod ule (Waters As-
soc. In c.) co ntainin g a s ili ca ca rtri dge was used . 
T he f1rst ext ra ct (co nta ining neu tral retin o ids) was ch ro m ate-
g rap hed isocratica ll y (Aow rate 1. 2 ml / min) in a mi xture ofhexa ne 
and eth yl aceta te (85: 15 v/ v) containin g 0 .5% ethano l and 0.05% 
acetic acid . 
T he second ex trac t (containin g acidi c reri no ids) was chro-
m atographed in a discontinuo us g rad ient chang ing the hexane to 
eth yl aceta te ratio (v/v) fro m 93:7 to 85: 15 at 6 min after inj ectio n 
of the sa mpl e (the so lvents were o th erw ise identica l. i.e., they 
con ta ined 0.5% ethano l and 0.05% aceti c acid). T he fl ow rate 
was I .4 ml / min and th e ti me between inj ectio ns (i ncl uding re-
equilibra tio n) was 35 min . 
Calibra tion and Quantitation Sta nd ard plots were prepared 
by add ing in creasing am oums of ret in o l, dehydro retin o l. isotre-
tin o in, and 4-oxo-i so trctino in to tes t tubes co ntaining the intern al 
stand ard so lutio n (250 J-LI ) and samples (20 m g) of vi tam in A-
depleted 11 6 1 skin (Figs I , 2). As a res ult of saponi ficatio n , th e 
ca rboxy li c acid of etrctin ate (intern al s tandard) was pa rti all y 
0.02 
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Figure 2. Ca lib ra ti on plots fo r retino l. dc-
h yd ro n:ti no l (a) . isotretinoin. and 4-oxo-iso-
t rct in o in (!>). 1\1[_,, !1'/,_, deno tes the m ass rati o of 
co mpo und to intern al standard. T he HPLC 
pea k heights (1-/, r111d H;,) we re measured at 
340 nn1 (neut ral retino ids) and 3(,5 11111 (acid ic 
ret in o ids). Fo r deta il s sec Fit; I . 
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(25-35'X•) co n ve rted w th e 13- ris co n fig uration (F ig liJ) and . co n-
ve rse ly. iso t ret in o in ;111d 4- oxo-iso tretin o in iso meri zed to the all -
lrO IIs confi g urati o n (25-35%, and 50-()() 'X,, n :specri ve ly). Sin ce the 
art ifa ctua l ris- tm11s iso meri za ti o n of 4-oxo-isotrct in o in w as no t 
in va ri ab ly propo rtiona l to th at o f th e in tema l s ta ndard , quanti-
lat io n was acco mpli shc·d b y relat in g th e sum of th e pea k he ig hts 
of 4-oxo-trctino in and 4- oxo-iso tn :tin o in to the sum of the ris 
and lrrw s iso m ers of the in te rn al s tanLbrd . In co ntra st , ret in o l. 
deh yd ro ret in o l. :rn d iso t ret. in o in wen: qu ;111 titated by sim ply IT-
bring the 1eak l_ll' ig h t of the parent compo und to that of th e 
ap prop ria te inte rnal sta ndard. 
T he cocffi ciem s of var ia ti o n fo r ana lys is o f retin o l. isotretin oi n , 
and 4- oxo-isotrct ino in in a patient 's serum w ere 6.7, 7.7. and H.7 
(w ithin- run ; n = 10), and 4 .4. 4 .3, and 12. 4 (bet w n :n-run ; n = 
4), respective ly. Dchyd ro reti no l co uld no t be assessed in this 
respect sin ce it is no t detecta ble in serum . ll y reverse-phase HPLC, 
howeve r, the coe ffi cie n ts of var iati o n fo r the analys is of epidermal 
re tin o l ;md deh yd ro n:tin o l arc s imil ar J1 3 J. S to ra ge fo r 3 m o nth s 
red uced the re tin o id co nce ntrJt io ns b y less than 5'Yu . 
Other Analyses Se rum IUH' and prGllbuntin con cen t rat io ns 
were m easured b y rad ial imm un o difti1sio n J17 Ju sin g co mmercial 
rabbit antisera ( lkh r in ~wc rkc AG, Ma rbur~. West G erm an y). 
3 
Stat istics Fo r st;Hi s ti ca l evaluati o n a 2-way analys is of va rian ce 
was e m p loyed Jl HJ. 
ltES UL TS 
Isotretinoin T he se rum and epiderma l co ncen trati o ns of iso-
trc tin o in and 4-oxo-i sor rct in o in d urin g and after treat m e m w ith 
isotrctin o in an: show n in Tab le l. In se rum . the m ain nt etabolire 
usuall y predom in ated over iso tret in oi n b y a fac to r of abo u t -+. 
T he conce n t rations of both co mpo und s re nui n t.:d fa irl y con sta n t 
d u rin g the initial 3 m o nth s o f th e rap y. Patien ts su bseq ue ntl y re-
ce iv in g 0.75 m g/ kg/da y, showed so m ew hat hi g her va lues J t 6 
m o n th s than at 3 m o nth s, alth o ug h the diftc rence w as no t s ta-
ti s t ica ll y sig nifi ca nt (a ll data not show n). 
T he ep id e rmal leve ls of th e d ru ' were low. In o rde r to obtain 
adeq uate m e:tsure m en ts , acidic ex tra cts of 3-5 skin sa mples were 
poo led prio r to HI'LC analys is. As see n in T able I, the predom-
in ance of 4- oxo-isotre t in o in ove r iso trerinoin w as less appa rent 
in th e sk in th an in the se rum . In the limi ted series o f sa mples , 
dose-re lated clu nges in the ep id e rm al drug con centratio n were 
no t assessable . H owever, I m o nth after di scominuati o n of the rapy 
the drug le vel in bo th epidermis and se rum was below th e d e-
tect io n li mit. 
Table I. Se rum and Epid e rmal Co nce n t rat io ns (Mea n ± SEM) o f lsot re tin o in and 4-0xo-isor reti no in Duri ng'' and After 
lso tret in oin T herap y 
Trca tm ~n t 
I m o m h 
.'\ III OIHh s 
(, III O II liJ S 
l'ns tt n .. ·a nn cn r 
I week 
2 Wl'L' k " 
~ we~k s 
Dos~ 












>~ S :unp l c :-. \\' t' IT o ht:~in 1.: d H- I X h :-~ l"t c r the b :-. t prev io u s dos~ . 
Scru rn 
lso trcti11 o in 4-0xo- i sotr~ti n o in 1' 
(ng/n li ) 
17 1 ± 23.2 S'J4 ± (,l\.4 
12H ± •1!1.7 (,34 ± (>3. 0 
154 ± 36. 0 (,4 2 ± 13 1 
6.5 - I .(, 12.H ± 6.4 
N IY1 1> .7 ± 2.7' 
N J) ND 
1
'T I1 c..· v.llll l.' !> du no t dist in gu i:-.h 4-oxo-i:-.ot.rcr in t.li n fro lll -l-n:xo- tn.: ti11oi n (:-...:~.: J\1clfrri.ds ttfld Al t'T II ild.,). 







1Not dl· tcclcd . The..· .lp p nlXilll. ll l' dc t..:ct inn lll ll i b were s llg l lld ro r SC I"I II Il (250 p.l ) and 211 n g / v, for l.' pidc.:r mi :-. (SO Ill ~) . 
' V :-lltl t: fnr p :Hi t·nt s treated fnr (l lll un\\t~: th c..· h:vl'l in p :uicnt ~ tr t.·:n cd fnr o nly 3 m c..mth\ w :-a s below rh c..· ~.k t cctkm \inll l. 
Ep idermis 
-------
lsotrcti no i11 4-0xo-isot rctinoin 
( n ~/~ wet ti ssue) 
6H.<J ± 14.(> 105 ± 18.6 
7( •. l) ± 2l:U 1211 ± 20.9 
HH'J ± 46. 1 12--l ± 37 .1 
ND N D 
----
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Table II. Snum Concentratio ns (M c:~ n ± SEM) of ltctin o l, IUW and l'n:a I bum in Ill Pati ents Tn:ated w ith O r:~l lso tretin o i1r' 
No . o r Dose l~et in o l I~ 13P l're;lib<llll in 
1'.1ricnrs (•n g/kg/da y) (J.Lg/dl) (J.Lg/ ml) (J.Lg/ nd) 
Prct rc:t tnl c n r 17 r. ~ . s :!: 5.43 40. ') :!: .on 26') :!: 7. :-> 
Trc3t i11 Cil t 
m o n rh 17 u.s (,2. (, ± (>. I (\ ]\) 2 ± .98 2(>7 ± 11 . 1 
3 n lo llrh s 17 0.5 (>.1. 4 :!: (> .78 .YJ . .J ± .75 2tlU :!: 7.2 
6 n1 onth s :-; 0.75 ()5 .8 :!: (). 7 1 .J. J. I :!: 2. (> 1 278 :!: 10. 9 
Po srtrcJt n> ellr 17 m.s :!: o. J<J 45.0 :!: 2.73 30 1 :!: 10 . 1 
( 1-J mollths) 
~one 0 ( rhL' v :Jiu c.:s l )hst-r vcd durin~ :111 d :1 licr ITT:tlmcn r dit"t i.:rt'd s i ~nil i t· .uJtl y (ru in th l· prctrc:l llll t' lll v,Jiucs (p > O.U5) . 
ln. th e sub cuti s no detectable am o un ts of 4-o:-;o-isotretin o in or 
isot r e tin o in were fo und durin g the fi rst 3 m o nth s of treJt lllL' Il t. 
In pat ients trc :~ rcd w ith th.c hi g he r dose o f the dru g, th e m ea n 
con c c ntrat iOil of 4-oxo-l so tretHl Olll was low (5 1 ng /g wet ti ss ue) 
and isot rct in o in was no t detected . At the f1rst fo llow-up , I m o nth 
a fte r withdraw:~ ] of thnapy, both co 111po un ds were und etect:~b lc 
(< 40 n g /g) in the subcuti s . 
Vita min A T he m ea n se rum con cL'ntrJ tions of ret in o l and its 
transpo rt pro te in s, IU31' and prea lbumin, did not a lter sig n ifi-
can tl y in associat io n with isotret ino in t reatm ent (Ta ble II ). N o 
dehydro rcti n o l was de tected in the se rum . 
T h e epiderma l contents of retin o l :~ nd d eh ydro rctin o l changed 
111 a 1·kcdl y durin g the treatmL' lH (Fig 3). T he mean co ncentrati o n 
o f ret in o l in creased fro m IHS ng /g befo re therap y to 293 ng / g 
afte r 3 m o nth s o f th e rap y (p < 0.01 ) . Con versely, th e m ea n 
d ehyd ro retinol leve l decreased fro m 78 ng / g to 18 ng / g VJ < 
0 . 00 1) :md in 4 o f th e p~ticnts th e le vel o f this co tnpo un d Jctuall y 
fel l be low the detect io n limit of the ass:~y (10 ng / g) . As seen in 
Fi g 3, in patients w ho con tinu ed to take iso trctin o in fo r an ad-
dit ion:d 3 m o n ths, the altered retin o l and dehydro rctin o l va luL'S 
p e rsisted unti l the dru g was d isco n tinued . l'retreatn1 e11t values 
were usua ll y rega ined w ithin I m o nth ~fter ccss:1t io n of thcr:1py. 
Jn 2 p lace bo-treated contro ls the epider m al va lues changed by 
less th an 20% ove r a 6-weck period (m ea n concemra tion s of 
retinol / d eh ydro ret in o l befo re and d urin g placebo: 162/ 52 ng / g 
and 189/ 4(J ng /g, respectively). 
T he subcutan eo us con centratio n of ret in o l did not change sig-
nifica ntl y durin g isotretino in tre:Hn1e11t (m ea n va lues 2 I 07, 2Uo3, 
and 1733 n g/g , befo re, durin g , and afte r th erapy) . Sin ce the con-
centratio n o f dch yd ron: tino l in th e subcutis was usua lly be low 
th e thres ho ld o f d etecti on (3U ng / g). the effect of iso tret in o in 011 
thi s s ubst:1 nce co uld no t be ev:du ated. 
D ISCUSSIO N 
Methodology Sever:d J-1 PLC m et hods have been described to r 
meas urin g isotreti no in in b lood 11 9-23 1. Unfo rtunatel y, no ne o f 
rh e rnc.t ho ds cou ld be app lied directl y to the dctcnninati o n o f 
isot r e tinoin J nd 4-oxo-i so trctin o in in cp id cnn al shave biops ies. 
Initia l experiments showed tha t in o rder to permit detection of 
sm a ll am o unts of isot retin o in i11 the skin , this co mpo un d had to 
be a n ea r ly e luent fi·o m the 1-l i'LC co lumn . Adso rptio n (no rm al-
ph ase) chro nu tog raph y on silica gel, performed w ith a disco n-
tinuous g radi en t, all owed simultam·ous ana lys is o f iso tre tin o in 
and 4-oxo-isotretin o in, w hi ch we re eluted in th at o rd er. A sin1ilar 
HPLC sys tem , but with o ut :1 g radi en t, was used fo r mc.JS uiT I11 eiH 
of re ti no l J nd de h yd roretin o l. T his assa y y ielded essenti all y th e 
same res u lts as reverse-phase Hl 'LC, bur gave so m ew hat hi g her 
se rum retin o l va lues than a Au orom ctri c assay used prev io us ly 
[11]. T h e m ain disadv:mtages of the no rm al-ph ase HJ>L C sys tem 
used we re th e lo ng run t in1 cs and the di fti cu ltics in achi ev in g 
co n s tant retention tim es dur ing g radient eluti on, particubrl y w hen 
rc tinoids w ere assayed in far-ri ch sa mples . 
In o rde r to obta in a quantitati ve recovery o f retin o ids fi·o m 
sk.in sa mpl es a h ydro ly ti c ex tractio n w as used. Fo r co ng ruence , 
the sera were ana lyzed w ith the sa m e hyd ro lytic procedure. 13y 
thi s pro ced ure t he ret in o id esters were saponi fied. Fur therm o re , 
so m e art ifa cru al iso meri za ti o ns occurred that were accounted tor 
in the stand :1rdization (sec J\1/ntcri,J/s 1111d i\1erlwds). 
T he sh :~ve-bi opsy tccllllique deserves specia l co mments. For an 
expn icnced o perato r it is qu ite poss ible to adj ust the cuttin g depth 
so that the skin s ~unpk w ill be unifo rm ly composed o ( :~bo u t 
60-70% ep id e rmi s 113 1. Sca rrin g is no t a p ro blem w ith this tech-
niqu e, a m atter of im porta nce w hen up to 5 biops ies arc required 
fro m o ne and the sa m e pati ent. Unfo rtun ately, the papi ll ary dcr-
tni s CO!lt:J I11in ar in g the epidermal sheets c um o t be rem oved w ith-
o ut ex posin g the sa mple to co nd iti o ns harm ful to th e un stable 
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Figure 3. Epiderma l concentrations (mean ± SEM) ot' (a) retin ol and 
(h) dchydro rctin ol in rela tion to isotrctinoin theropy. All patients received 
J dose of0 .5 mg/ kg/day fi.> r rhe first 3 monrhs. At the end of th is period 
the 111 ca n retinol and dchydroretino l va lues did not di ffer bet ween patiems 
who subsequentl y received trco unenr ;md those who did nor. 
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rc tinoids. H owever, thi s "conta min atio n" d ocs not appear to 
contribute s ignifi ca ntl y to the variabi li ty o f epid ermal re tin o id 
va lu es 11 3] ::111d sho uld certainl y no t res ult in spurio us chan ges in 
retinoid mean levels o bserved at different times of the rap y. 
Phannacodynamics O lir res ults for th e serum concentrations 
of iso tretino in 8-18 h after an o ral d ose of app rox imatel y 25 m g 
b.i.d. arc in acco rdan ce with those of Brazzell et al 122'1, w ho 
used a different an :1lytica l procedure. Thus. during chronic dos-
in g, 4-oxo-i sotrcti no in predominated 4- to 5-fo ld over the pa rent 
drug. O ther metaboli tes, such as tretinoin, 11 , 13-d i-cis-tretin o in , 
and 4-oxo-tret in o in [23 ], accounted for less than 10% of th e drug 
concentration in a few sera ex tracted w itho u t hydrolysis (Ro llman 
and Vahlqui st, unpublished observatio ns), bur we re not assessable 
i1i h yd ro lyzed sa mples. The eliminatio n of isotretin o in from the 
blood was rap id, especiall y co mpared w ith that of the aromatic 
ret in o id et rc tin atc 124 1. 
To the best of o ur kn owledge, no previous in vestigat io n o n 
the distribution of isorret in o in in hum an skin has been unde r-
taken. We fo un d that tlic drug co ncentrati o ns were generall y 
lowe r in the epidermis than in the serum. This diffe rence was 
es peciall y evident for 4-oxo-isotretinoin , a compound of un-
known biologic s ig nifi ca nce . 
T he tota l epiderma l co ncentrati o n (parent co mpo und p lu s m ain 
m etabolite) of isotn: tin o in is similar to that o f et ret in ate, but in 
the subcuti s these co ncentra t io ns differ mark edl y 11 4 1. Th us, ctre-
tinate accumulates in fat tissue, res ultin g in a ve ry lo ng bio logic 
half-life of the drug [24 ], w hereas isotrctinoin seems to be devoid 
of affi nity to this tiss ue co mpartm ent. T he question of w hethe r 
isot·ret in o in accumula tes in the sebaceous g land s, essenti al targets 
in the tre~tmcnt of K ne, re m ain s to be clu cid~ted. 
Interaction with Vitamin A The effect of so m e synth eti c re-
tinoids o n the t ra1·1sport and m etabo lis m of v itamin A has been 
in vestigated previous ly in both hum ans and experim ental ani-
m als. For exa mple, in rats fed w ith isotrctin o in 125 1 o r trctinoin 
126,27 1, th e p las m a leve l of retinol decre::Jscd, presumably by 
feedback inhibiti o n of its release fro m the li ve r 126,271. By co n-
trast. increased serum vitamin A le vels were o bserved in 3 patients 
treated wi th tretinoin for fol licular keratoses 128]. In o ur se ries 
of isotrctin o in-treated patients there we re no sig nifi cant changes 
in th e serum levels of ret in o l, RBP , o r prea lbumin (transthyretin). 
Analo go usly, 2 previous studies 129,301 showed no e ffect of ctrc-
tinatc o n the plas m a transport of vita min A in hum ans. 
O n the other hand , we recentl y repo rted that e trc tinate therapy 
redu ced the epide rm al ret in o l leve l and sli g htl y in creased the leve l 
of dchydro reti no l in the no rm al sk in of patients w ith ke rat ini zin g 
diso rdc1·s \1 4]. lsot retin o in , w hich indu ces si milar st ru ctural changes 
in epide rmi s (e .g., xerosis, pee lin g, :111d dermatitis) as e tret in ate 
13 ], had quite a different effect o n the ep id erm al vitamin A con-
tent. The concen t ratio n of retin o l in the ep idermis alm ost doubled 
and th e deh yd ro ret in o l conccntrn io n decreased to o ne- fifth of 
the original va lue. T hese effects, w hi ch were revnsiblc afte r ces-
sation of therapy and did not appe:J r during phccbo treatment, 
could fo r obv io us reasons no r be the res ult of a chan ged pla s m a 
transpo rt of ret in ol to the skin . We find it more li ke ly that al-
terati o n s in the loca l v itamin A m etabo li sm arc in volved. Sin ce 
isotrcrinoin ca nn ot be con verted to retin o l in the ti ss ue 13 1 j. the 
in crease in epidcn,na l retino l in duced by the tn.:a tmeJH is probab ly 
due eith er to s timulated uptake of retinol to kcratin ocy tcs or to 
inh_ibitiOJ) of the retinol metabolism in th e cell s. 
T he f:1cto rs regulatin g the cp idcrnu l dchydrorctino l le ve l arc 
v irtuall y unknown. Dchydroretinol (o r its co ngener in unhydro-
lyzcd skin) is an in situ m etaboli te of retino l w hi ch accumulates 
in conn ection w ith epi der mal h ypc rpro life rat io n [II ,32-341. A 
situatio n in w hich dchydrorctinol is decreased has not previously 
been enco un te red. 1-l o pcfull y, the inte ra ct ions between isotreti-
no in and end ogenous retinol and dehydroretinol, m ay be in stru-
mental in future inves ti g~ti on s of the f.1cto rs rcgul~tin g epidermal 
vita min A m etabo lis m. 
THE JOU I~NA L l F INVESTIGATIVE DE I~MATOLOGY 
It is no t known w hether the chan ge in the epid erm al vita min 
A compos iti o n induced b y isotrctin o in therapy is specifi c for acne 
patients. In the present series th e treatment rai sed th e ·dcercascd 
ep idermal retino l co ncentrati o ns fo und in untrea ted acne patients 
11 1], but there was no appa rent correla tio n between th e clinical 
response to isotrctin o in and the change in epider mal v itamin A 
co mp ositio n durin g treatment (res ults not show n). H owever, this 
d ocs not excl ude the poss ibility that the effects o n epitheli a l vi-
tamin A arc inv o lved in the m echani sm of acti o n of isotretinoin . 
We arc iudcbted to Dr. G. Miclwiilsso u .for r~fim·ius paticuts to"-' · The ua /11ab/e 
assistfl l/ ((' of Mr. U. PcttCI'SSO II ; Rochc-Prodllktcr A13 , S Ju cdm , is sratcfitiiy 
nri.:II OII' Icdged. We also ll'nllt to tl11111k C. El.:boluu , PI1. D. , _fJ r stntistirn l ad I' iCC 
allfll . Pihi-Luudi11 , E. f-la,r!]orsm, a11tl A. A udersso11 _l{>r expert tcrhuicn l 11elp . 
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